Partner A: $149 per vial. Partner B: $189 per vial. Partner B wins.
Until you add supply duration and every fee row. Partner A is a 14-day vial with $12 processing and $29 shipping. Partner B is 28 days at the same strength with fees disclosed upfront. Partner B costs less per patient-month. That is the compounding pharmacy price comparison trap national telehealth ops teams describe when they say they need to compare pricing from different pharmacy partners. If your team is still asking whether compounding pharmacies are cheaper, the answer is landed cost per patient-period, not vial price alone.
This guide defines the five rows every comparison chart needs, shows a whale-ready worksheet spec, and ties landed math to member quoting before checkout.
Who this is for
This article is for clinic ops leads, pharmacy coordinators, and founder-led telehealth finance owners who evaluate 503A compounders and build internal price comparison charts.
You are not the audience if you are a patient comparing retail coupons or a prescriber asking about clinical dosing. Consumer price apps solve a different problem. This is coordinator-side B2B economics only. It is not medical advice.
The scene ops teams describe on vendor calls
On a recent discovery call with a national telehealth team, ops walked through the same pricing friction we hear from scaled weight-loss and hormone brands:
- “Are these base prices?”
- “Shipping fee… processing fee…”
- “How much would it be a month, two months, worth of medication?”
- “We need to compare currently the pricing from our different pharmacy partners.”
They were not asking for a portal tour. They needed a credible comparison chart so leadership could pick partners and reset member tiers without rebuilding spreadsheets every quarter.
We need apples-to-apples landed cost per patient, for the same strength and supply duration, before we commit.
That is a chart discipline problem. The fix is row structure, not a better PDF export.
Why compounding pharmacy price comparisons fail
Most failed comparisons share one pattern: partners quote on different assumptions and ops paste numbers into columns that do not share the same rows.
| Failure mode | What ops did | What broke |
|---|---|---|
| Vial price only | Ranked on headline medication line | Supply duration and fees flipped the winner |
| Mixed supply periods | Compared one-month and two-month vials | Cheaper sticker, higher patient-month cost |
| Base price as landed cost | Quoted members from catalog teaser | Processing and shipping ate margin on invoice |
| Bundled platform markup | Treated drug line as COGS | Real cost hidden inside “base price” |
| No refresh cadence | Kept last quarter’s chart | Partner fee change silently moved COGS |
The outcome ops buyers name is simple: quote patients from numbers you trust before checkout, not invoice archaeology after orders ship.
The five rows every chart needs
Field teams send whale follow-up comparison charts with a fixed row structure. Collapse the detail into five mandatory rows before you add partner columns.
| Row | What it captures | Why it cannot be blank |
|---|---|---|
| 1. Product definition | Medication name, strength, concentration or package | Different concentrations are different SKUs, not interchangeable vials |
| 2. Approximate days of supply | Patient-period the vial is meant to cover | Without this row, vial price is meaningless |
| 3. Base medication price | Compounder line item for that SKU | Must match the supply duration on row 2 |
| 4. Checkout fees | Facilitation, processing, shipping | Often omitted from first quote, always on invoice |
| 5. Estimated landed cost | Sum of rows 3 and 4 for one vial | The number ops rank and quote from |
If any row is missing for one partner, you are not ready to pick a winner.
Row 4 is where most charts fail. Ask every rep: is facilitation bundled in the drug line or disclosed separately? Does processing hit per order or per line? Is shipping flat nationwide or tiered by zone?
Five-row comparison chart (whale worksheet spec)
Build every partner column on these five rows before you rank vendors. Example: semaglutide 2.5 mg/mL at three compounders.
| Row | Partner A | Partner B | Partner C |
|---|---|---|---|
| 1. Product definition | Semaglutide 2.5 mg/mL, 1 mL vial | Semaglutide 2.5 mg/mL, 2 mL vial | Semaglutide 2.5 mg/mL, 1 mL vial |
| 2. Approximate days of supply | 28 days | 28 days (verify SIG) | 56 days |
| 3. Base medication price | $165 | $149 | $189 |
| 4. Checkout fees | Facilitation bundled; processing $12; shipping $29 | Facilitation $8; processing $0; shipping $19 | Facilitation bundled; processing $15; shipping $29 |
| 5. Estimated landed cost | $206 | $176 | $233 |
Partner B looked cheapest on base medication price alone. Partner C looked expensive on vial sticker price. After row 2 and row 4, the ranking depends on whether you need one vial per 28 days or can normalize a 56-day supply.
Normalized landed cost per 28 days: Partner A $206, Partner B $176, Partner C $116.50 (divide $233 by 56 days, multiply by 28).
That normalization step is why row 2 is non-negotiable. For a full fee-by-fee column spec, see our apples-to-apples 503A pricing guide.
Outcome hooks: what the chart unlocks
A complete five-row chart is not paperwork. It is how ops teams buy back margin and speed.
Fewer wrong member quotes. When landed cost is settled before checkout, finance sets membership tiers from COGS they can defend. Wrong quotes are harder to unwind than a slow vendor decision.
Faster partner decisions. Leadership can compare three compounders on one screen instead of three PDFs with different row labels. The chart becomes the shared language between ops, finance, and the founder.
Apples-to-apples routing. Many clinics route GLP-1 to one partner and hormones to another. The five-row structure lets you compare within category and map SKUs to partners without averaging unrelated lines. The workflow lives in our multi-partner prescription price comparison guide.
Supply duration clarity. One-month vs two-month vials are different products on the chart, not a discount tier. When ops normalize days of supply, two-month quotes stop looking like automatic wins. See month vs two-month compound supply pricing for the normalization math.
GLP-1 quoting confidence. Semaglutide and tirzepatide drive volume for weight-loss and telehealth brands. Run those lines through the five-row chart first. For titration-specific detail, use landed cost per vial before you quote semaglutide.
Expand row 4 when you tighten numbers
The five-row chart is the minimum for screening vendors. When you move from shortlist to contract, expand row 4 into separate lines on the same worksheet:
| Fee line | Example (semaglutide) |
|---|---|
| Facilitation fee | $8 disclosed, or “bundled in drug” |
| Processing | $12 per order |
| Shipping | $29 flat nationwide |
Add optional inputs only when you are tightening numbers, not on the first pass: rough monthly order volume and card vs ACH mix at checkout.
No pharmacy partner column is required for internal math. Add partner names only after rows 1 through 5 are complete for every column.
Five mistakes that break compounding price charts
1. Skipping row 2 (supply duration).
You cannot compare vial prices if supply duration is not on the same row. A $149 vial that covers 14 days loses to a $189 vial that covers 28 days at the same strength.
2. Treating row 3 as row 5.
Base medication price is not landed cost. Row 4 exists because processing and shipping hit at checkout even when reps call the drug line “all-in.”
3. Mixing one-month and two-month rows without normalization.
Give each supply period its own column or normalize to cost per 28 days before you sort.
4. Ignoring bundled markup in row 3.
Some portals bake 40 to 80 percent intermediary markup into the medication line. Row 3 should reflect pass-through drug cost when the platform discloses it.
5. Quoting patients before row 5 is complete.
Build the chart first, set member pricing second. Field teams rank pricing transparency alongside support quality. A partner you cannot chart is a partner you cannot defend to your CFO.
Questions to ask before you add a partner column
Use this checklist on demos and reference calls:
- Is catalog price row 3 only or does it include row 4 fees?
- What processing fee applies per order vs per line?
- How does shipping work for your states (flat, tiered, cold chain)?
- Is there a facilitation fee separate from the drug, or is it bundled?
- Can you export the same strength and days of supply we order today?
- Does price in catalog match price at checkout?
If answers shift between catalog browse and checkout, your chart is building on sand.
Where Fizy Health fits (honest framing)
Fizy Health is built for clinics that already use 503A compounders and need one ordering layer with economics you can see before you commit.
Pass-through pricing shows resolved per-vial 503A cost in the medication catalog and on every cart line. Checkout separates drug cost from disclosed facilitation before card authorization, so your five-row worksheet matches what coordinators see on screen.
That is the proof behind the outcome: landed cost per patient-period on the same strength and supply duration before you quote.
Telehealth-specific context lives on the telehealth ops page. Platform fee structure is on the pricing page. For routing after you rank partners, see multi-pharmacy routing.
Bottom line
A compounding pharmacy price comparison only works when every partner sits on the same five rows: product definition, supply duration, base medication price, checkout fees, and estimated landed cost.
Build the chart before you quote members. The cheapest vial on a PDF is rarely the cheapest patient-month once row 4 runs at checkout.